EXPEDITED REVIEW
Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions
Lisette Okkels Jensen, MD, PhD*,*,
Michael Maeng, MD, PhD ,
Anne Kaltoft, MD, PhD,
Per Thayssen, MD, DMSci*,
Hans Henrik Tilsted Hansen, MD ,
Morten Bottcher, MD, PhD,
Jens Flensted Lassen, MD, PhD,
Lars Romer Krussel, MD, DMSci,
Klaus Rasmussen, MD, DMSci, ,
Knud Noerregaard Hansen, MD*,
Lars Pedersen, MSc||,
Soeren Paaske Johnsen, MD, PhD,||,
Henrik Toft Soerensen, MD, DMSci, PhD||,¶ and
Leif Thuesen, MD, DMSci
* Department of Cardiology, Odense University Hospital, Odense, Denmark
Department of Cardiology, Skejby Sygehus University, Aarhus, Denmark
|| Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
Department of Cardiology
Center of Cardiovascular Research, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark
¶ Department of Epidemiology, Boston University, Boston, Massachusetts
Manuscript received April 4, 2007;
revised manuscript received May 21, 2007,
accepted June 3, 2007.
* Reprint requests and correspondence: Dr. Lisette Okkels Jensen, Department of Cardiology, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark (Email: okkels{at}dadlnet.dk).
Objectives: The aim of the study was to examine outcomes subsequent to implantation of drug-eluting stents (DES) and bare-metal stents (BMS).
Background: Use of DES might be associated with increased risk of stent thrombosis (ST), myocardial infarction (MI), and death.
Methods: From January 2002 through June 2005, data from all percutaneous coronary interventions in western Denmark were prospectively recorded in the Western Denmark Heart Registry; 12,395 consecutive patients (17,152 lesions) treated with stent implantation were followed for 15 months. Data on death and MI were ascertained from the national databases. The Academic Research Consortium definition of ST was used.
Results: The DES were implanted in 3,548 patients (5,422 lesions) and BMS were implanted in 8,847 patients (11,730 lesions). Definite, probable, or possible ST was found in 190 (2.15%) patients in the BMS group and in 64 (1.80%) patients in the DES. The risk of definite ST was similar in the 2 groups (DES: 0.65%; BMS: 0.61%). Very late definite ST (between 12 and 15 months after implantation) occurred more frequently in patients receiving DES (hazard ratio [HR] 10.93, 95% confidence interval [CI] 1.27 to 93.76). Also, the risk of MI between 12 and 15 months after implantation was higher in the DES group (HR 4.00, 95% CI 2.06 to 7.79). Mortality was similar in the 2 groups. Target lesion revascularization was reduced by 43% in patients treated with DES (HR 0.57, 95% CI 0.48 to 0.67).
Conclusions: The minor risk of ST and MI within 15 months after implantation of DES seems unlikely to outweigh the benefit of these stents.
|
Abbreviations and Acronyms
| | BMS = bare-metal stent(s) | | CI = confidence interval | | DES = drug-eluting stent(s) | | FDA = Food and Drug Administration | | HR = hazard ratio | | MI = myocardial infarction | | PCI = percutaneous coronary intervention | | ST = stent thrombosis | | TLR = target lesion revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
J. Daemen, K. H. Kuck, C. Macaya, V. LeGrand, M. Vrolix, D. Carrie, I. Sheiban, M. J. Suttorp, P. Vranckx, T. Rademaker, et al.
Multivessel Coronary Revascularization in Patients With and Without Diabetes Mellitus: 3-Year Follow-Up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) Trial
J. Am. Coll. Cardiol.,
December 9, 2008;
52(24):
1957 - 1967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/writing members, J. Daemen, M. L. Simoons, W. Wijns, A. Bagust, G. Bos, J. M. Bowen, E. Braunwald, E. Camenzind, B. Chevalier, et al.
Meeting Report * ESC Forum on Drug Eluting Stents * European Heart House, Nice, 27-28 September 2007
Eur. Heart J.,
November 26, 2008;
(2008)
ehn510v1.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Pfisterer, H. P. Brunner-La Rocca, P. Rickenbacher, P. Hunziker, C. Mueller, F. Nietlispach, G. Leibundgut, F. Bader, C. Kaiser, and for the BASKET Investigators
Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET
Eur. Heart J.,
November 25, 2008;
(2008)
ehn516v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. O. Jensen, M. Maeng, P. Thayssen, E. H. Christiansen, K. N. Hansen, A. Galloe, H. Kelbaek, J. F. Lassen, and L. Thuesen
Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial
Eur. Heart J.,
November 2, 2008;
29(22):
2733 - 2741.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Shishehbor, S. S. Goel, S. R. Kapadia, D. L. Bhatt, P. Kelly, R. E. Raymond, J. M. Galla, S. J. Brener, P. L. Whitlow, and S. G. Ellis
Long-Term Impact of Drug-Eluting Stents Versus Bare-Metal Stents on All-Cause Mortality
J. Am. Coll. Cardiol.,
September 23, 2008;
52(13):
1041 - 1048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Anstrom, D. F. Kong, L. K. Shaw, R. M. Califf, J. M. Kramer, E. D. Peterson, S. V. Rao, D. B. Matchar, D. B. Mark, R. A. Harrington, et al.
Long-term Clinical Outcomes Following Coronary Stenting
Arch Intern Med,
August 11, 2008;
168(15):
1647 - 1655.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Rastan, E. Boudriot, V. Falk, A. P. Kappetein, M. A. Borger, P. W. Serruys, G. Schuler, and F. W. Mohr
Frequency and pattern of de-novo three-vessel and left main coronary artery disease; insights from single center enrolment in the SYNTAX study
Eur. J. Cardiothorac. Surg.,
August 1, 2008;
34(2):
376 - 383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Austin, K. G. Oldroyd, A. McConnachie, R. Slack, H. Eteiba, A. D. Flapan, K. P. Jennings, R. J. Northcote, A. C.H. Pell, I. R. Starkey, et al.
Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications: A Propensity Score-Matched Outcome Study
Circ Cardiovasc Intervent,
August 1, 2008;
1(1):
45 - 52.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2355 - 2369.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-H. Choi, A. Prasad, and S. Tsimikas
The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents.
J. Am. Coll. Cardiol.,
June 10, 2008;
51(23):
2228 - 2229.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jabs, S. Gobel, P. Wenzel, A. L. Kleschyov, M. Hortmann, M. Oelze, A. Daiber, and T. Munzel
Sirolimus-induced vascular dysfunction increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation.
J. Am. Coll. Cardiol.,
June 3, 2008;
51(22):
2130 - 2138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W. Groeneveld, M. A. Matta, A. P. Greenhut, and F. Yang
Drug-Eluting Compared With Bare-Metal Coronary Stents Among Elderly Patients
J. Am. Coll. Cardiol.,
May 27, 2008;
51(21):
2017 - 2024.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mauri and S.-L. T. Normand
Studies of Drug-Eluting Stents: To Each His Own?
Circulation,
April 22, 2008;
117(16):
2047 - 2050.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Grines, J. A. Goldstein, and R. D. Safian
Should We Routinely Use Drug-Eluting Stents for Acute Myocardial Infarction?: Let's Wait and See
J. Am. Coll. Cardiol. Intv.,
April 1, 2008;
1(2):
136 - 138.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Pfisterer, H. P. Brunner-La Rocca, and C. Kaiser
The balance of risks and benefits of drug-eluting versus bare-metal stents.
J. Am. Coll. Cardiol.,
March 4, 2008;
51(9):
972 - 972.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Thuesen, L. O. Jensen, A. Kaltoft, and M. Maeng
Reply.
J. Am. Coll. Cardiol.,
March 4, 2008;
51(9):
972 - 973.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Grines
Off-label use of drug-eluting stents putting it in perspective.
J. Am. Coll. Cardiol.,
February 12, 2008;
51(6):
615 - 617.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Saia, A. Marzocchi, and A. Branzi
Review: The safety of drug-eluting stents
Therapeutic Advances in Cardiovascular Disease,
February 1, 2008;
2(1):
43 - 52.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Austin, J. P Pell, and K. G Oldroyd
Drug-eluting stents: do the risks really outweigh the benefits?
Heart,
February 1, 2008;
94(2):
127 - 128.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Buttner and F.-J. Neumann
Peeling-Off Labels: Mounting Evidence for Benefit of Drug-Eluting Stents With Off-Label Use
J. Am. Coll. Cardiol.,
November 20, 2007;
50(21):
2037 - 2038.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Bare-Metal or Drug-Eluting Stents for Coronary Artery Disease?
Journal Watch Cardiology,
August 29, 2007;
2007(829):
2 - 2.
[Full Text]
|
|
|
|
